Advanced Colorectal Cancer
Clinico-Pathological and Molecular Factors with Prognostic Importance, and Potential Predictive Markers of Response to Modern Systemic Treatments
References
Surveillance, Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 17 Regs Limited-Use, Nov 2006 Sub (1973-2004 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission. Accessed May 2013.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, Eds. AJCC cancer staging manual (7th ed). New York, NY: Springer 2010; p. 143.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012; 62(1): 10-29. http://dx.doi.org/10.3322/caac.20138
Bleiberg H. Role of chemotherapy for advanced colorrectal cancer. New oportunities. Semin Oncol 1996; 23(1 Suppl 3): 42-50.
de Gramont A, Louvet C, Andre T, Tournigand C, Krulik M. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998; 34: 619-26. http://dx.doi.org/10.1016/S0959-8049(97)00364-X
Capdevila J, Elez E, Peralta S, Macarulla T, Ramos FJ, Tabernero J. Oxaliplatin-based chemotherapy in the manage- ment of colorectal cancer. Expert Rev Anticancer Ther 2008; 8: 1223-36. http://dx.doi.org/10.1586/14737140.8.8.1223
Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun Chen S, Chen CM. How aggressive should we be in patients with stage IV colorectal cancer? Dis Colon Rectum 2003; 46(12): 1646-1652. http://dx.doi.org/10.1007/BF02660770
Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, GrantDR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006; 202(3): 468-75. http://dx.doi.org/10.1016/j.jamcollsurg.2005.11.008
Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112: 1096-1102. http://dx.doi.org/10.1016/S0016-5085(97)70119-7
Eker B, Ozaslan E, Karaca H, Berk V, Bozhurt O, Inanc M, et al. Factors affecting prognosis in metastatic colorrectal cancer patients. Asian Pac J Cancer Prev 2015; 16: 3015-21. http://dx.doi.org/10.7314/APJCP.2015.16.7.3015
Miyamoto Y, Hayashi N, Sakamoto Y, Ohuchi M, Tokunagam R, Kurashige J, et al. Predictors of long-term survival in patients with stage IV colorectal cancer with multi-organ metastases: a single center retrspective analysis. Int J Clin Oncol 2015; published online.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitu- mumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34. http://dx.doi.org/10.1200/JCO.2007.14.7116
Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65. http://dx.doi.org/10.1056/NEJMoa0804385
Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308. http://dx.doi.org/10.1038/nrc2109
Natsumi I, Yoshifumi B, Katsuhiko N, et al. NRAS mutations are rare in colorrectal cancer. Diagn Mol Pathol 2010; 19: 157-163. http://dx.doi.org/10.1097/PDM.0b013e3181c93fd1
De Roock W, Bernasconi D, De Schutter J, et al. Effects of KRAS, BRAF, NRAS and PIK3Ca mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorrectal cancer: a retrospective consortium análisis. Lancet Oncol 2010; 11: 753-62. http://dx.doi.org/10.1016/S1470-2045(10)70130-3
Gerber HP, Ferrara N. Pharmacology and pharmaco-dynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65: 671-80.
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079-89. http://dx.doi.org/10.1038/sj.onc.1201047
Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 1993; 90: 7533-7. http://dx.doi.org/10.1073/pnas.90.16.7533
Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400: 468-72. http://dx.doi.org/10.1038/22788
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expres- sion: implications for induction and inhibition of tumor angio- genesis. Cancer Res 1995; 55: 4575-80.
Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3: 219-31. http://dx.doi.org/10.1016/S1535-6108(03)00030-8
Klump B, Nehls O, Okech T, Hsieh CJ, Gaco V, Gittinger FS, et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis 2004; 19: 23-42. http://dx.doi.org/10.1007/s00384-003-0499-7
Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-74. http://dx.doi.org/10.1200/JCO.2009.23.3452
Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor loca- tion, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-9. http://dx.doi.org/10.1093/jnci/dji174
De Rook W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastasic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-62. http://dx.doi.org/10.1016/S1470-2045(10)70130-3
Pai RK, Jayachandran P, Koong AC, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36: 744-52. http://dx.doi.org/10.1097/PAS.0b013e31824430d7
Russo AL, Borger DR, Szymonifka J, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer 2014; 120: 1482-90. http://dx.doi.org/10.1002/cncr.28599
Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 2014; 120: 2316-24. http://dx.doi.org/10.1002/cncr.28729
Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065- 1075. http://dx.doi.org/10.1016/S1470-2045(14)70330-4
Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337. http://dx.doi.org/10.1038/nature11252
Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23: 2965-2970. http://dx.doi.org/10.1158/1055-9965.EPI-14-0654
Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19: 462-468. http://dx.doi.org/10.1158/1078-0432.CCR-12-2625
Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523. http://dx.doi.org/10.1158/2159-8290.CD-11-0109
Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in Her-2 amplified metastatic colorectal patients (mCRC): The HERACLES trial. J Clin Oncol 2015; 33: (suppl;abstr 3508). (HERACLES Trial EudraCT 2012002128-33).
Aisner DL, Nguyen TT, Paskulin DD, et al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 2014; 12: 111-118. http://dx.doi.org/10.1158/1541-7786.MCR-13-0479-T
Zeng ZS, Weiser MR, Kuntz E, et al. C-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265: 258-269. http://dx.doi.org/10.1016/j.canlet.2008.02.049
